• 1
    Kirby RS, Roehrborn C, Boyle P et al. for the PREDICT Study investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia. The Prospective European Doxazocin and Combination Therapy (PREDICT) Trial. Urology 2003; 61: 11926
  • 2
    Lepor H, Williford WO, Batty MJ et al. for the Veterans Affair Cooperative Studies Benign Prostatic Hyperplasia Study group: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 5339
  • 3
    Kirby RS. A randomised, double-blind crossover study of tamsulosin and controlled release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003; 91: 414
  • 4
    Roehrborn CG, Boyle P, Bergner D et al. for the PLESS Study Group. Serum prostate-specific antigen and prostate Volume predicts long term changes in symptoms and flow rate, results of a four-year, randomised trial comparing finasteride versus placebo. Urology 1999; 54: 6629
  • 5
    McConnell JD, Bruskewitz R, Walsh P et al. for the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 55763